Dimerix (ASX:DXB) Successfully Completes IDMC Review for ACTION3 Phase 3 Trial
Dimerix (ASX:DXB) successfully completes IDMC review of ACTION3 Phase 3 trial, affirming DMX-200’s safety profile.
Category: Healthcare
AFT Pharmaceuticals (ASX:AFP) Reports Record Annual Revenue
AFT Pharmaceuticals (ASX:AFP) reports a 6% increase in FY25 revenue, targets $300M by FY27, and declares an increased dividend.
Oceania Healthcare (ASX:OCA) Reports FY25 Results and Strategic Initiatives
Oceania Healthcare (ASX:OCA) reports FY25 results, highlighting financial performance and strategic initiatives for future growth.
Chimeric Therapeutics (ASX:CHM) Announces $6.6 Million Placement to Advance Clinical Trials
Chimeric Therapeutics (ASX:CHM) announces a $6.6 million placement to fund key clinical trials in its cell therapy pipeline.
Monash IVF Group (ASX:MVF) Updates FY25 Profit Guidance
Monash IVF Group (ASX:MVF) revises FY25 Underlying NPAT guidance to $27.5m, reflecting softer market conditions.
Noxopharm Limited (ASX:NOX) Raises $2.5 Million from Nyrada Share Sale
Noxopharm Limited (ASX:NOX) raised $2.5 million through a share sale to fund upcoming clinical trials and R&D initiatives.
Vitura Health Limited (ASX:VIT) Acquires Heyday Medical Clinic
Vitura Health Limited (ASX:VIT) through its Flora joint venture acquires Heyday Medical Clinic, enhancing its holistic healthcare network nationally.
Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant symptom relief trends.
HITIQ Limited (ASX:HIQ) Announces Entitlement Issue to Raise up to $2.92 Million
HITIQ Limited (ASX:HIQ) launches a non-renounceable entitlement issue aiming to raise up to $2.92 million to expand manufacturing and USA operations.
Chimeric Therapeutics (ASX:CHM) Reports Positive ADVENT-AML Trial Results
Chimeric Therapeutics (ASX:CHM) reports that two of three patients achieved complete response in its ADVENT-AML Phase 1B clinical trial.